This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
MK-1775
Accession Number
DB11740
Type
Small Molecule
Groups
Investigational
Description

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
AZD 1775 / AZD-1775 / AZD1775 / MK 1775 / MK-1775 / MK1775
Categories
Not Available
UNII
K2T6HJX3I3
CAS number
955365-80-7
Weight
Average: 500.607
Monoisotopic: 500.264822302
Chemical Formula
C27H32N8O2
InChI Key
BKWJAKQVGHWELA-UHFFFAOYSA-N
InChI
InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
IUPAC Name
1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-3-one
SMILES
CN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AWee1-like protein kinase
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
24856436
PubChem Substance
347828098
ChemSpider
24808590
ChEBI
91414
ChEMBL
CHEMBL1976040
HET
8X7
PDB Entries
5v5y / 5vd0 / 5vdk

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingNot AvailableGBM / Glioblastomas1
0RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Peritoneum Cancer1
1Active Not RecruitingTreatmentCancer of the Ovary / Locally Advanced Solid Tumors / Locally Advanced Solid Tumours / Metastatic Solid Tumors / Metastatic Solid Tumours1
1Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
1Active Not RecruitingTreatmentOvarian Cancer, TNBC, SCLC, Other Solid Tumours / Ovarian Cancer, TNBC, SqNSCLC, and Other Solid Tumours1
1CompletedTreatmentAdvanced Solid Tumours1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentAdult Glioblastoma / Recurrent Adult Brain Neoplasm / Recurrent Glioblastoma1
1RecruitingTreatmentAdvanced Solid Tumours1
1RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Diffuse Intrinsic Pontine Glioma (DIPG) / Diffuse Midline Glioma, H3 K27M-Mutant / Glioblastomas / Gliosarcoma / Untreated Childhood Anaplastic Astrocytoma / Untreated Childhood Anaplastic Oligoastrocytoma / Untreated Childhood Anaplastic Oligodendroglioma / Untreated Childhood Brain Stem Glioma / Untreated Childhood Giant Cell Glioblastoma / Untreated Childhood Glioblastoma / Untreated Childhood Gliosarcoma1
1RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
1RecruitingTreatmentEndometrioid Adenocarcinoma / Recurrent Cervical Carcinoma / Stage I Uterine Corpus Cancer / Stage I Uterine Corpus Cancer AJCC v7 / Stage I Vaginal Cancer / Stage I Vaginal Cancer AJCC v6 and v7 / Stage IA Uterine Corpus Cancer / Stage IA Uterine Corpus Cancer AJCC v7 / Stage IB Cervical Cancer / Stage IB Cervical Cancer AJCC v6 and v7 / Stage IB Uterine Corpus Cancer / Stage IB Uterine Corpus Cancer AJCC v7 / Stage IB2 Cervical Cancer AJCC v6 and v7 / Stage II Cervical Cancer / Stage II Cervical Cancer AJCC v7 / Stage II Uterine Corpus Cancer / Stage II Uterine Corpus Cancer AJCC v7 / Stage II Vaginal Cancer / Stage II Vaginal Cancer AJCC v6 and v7 / Stage IIA Cervical Cancer / Stage IIA Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage III Cervical Cancer / Stage III Cervical Cancer AJCC v6 and v7 / Stage III Uterine Corpus Cancer / Stage III Uterine Corpus Cancer AJCC v7 / Stage III Vaginal Cancer / Stage III Vaginal Cancer AJCC v6 and v7 / Stage IIIA Cervical Cancer / Stage IIIA Cervical Cancer AJCC v6 and v7 / Stage IIIA Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer AJCC v7 / Stage IIIB Cervical Cancer / Stage IIIB Cervical Cancer AJCC v6 and v7 / Stage IIIB Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer AJCC v7 / Stage IIIC Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer AJCC v71
1RecruitingTreatmentHypopharynx Squamous Cell Carcinoma / Laryngeal Cancer / Oral Cavity Squamous Cell Carcinoma1
1RecruitingTreatmentMalignant Lymphomas / Neoplasms1
1RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingTreatmentMuscle Invasive Bladder Cancer1
1RecruitingTreatmentOvarian, Breast, and Second-Line Small Cell Lung Cancer / Refractory Solid Tumours / Relapsed Small Cell Lung Cancer (SCLC)1
1SuspendedTreatmentStage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer1
1TerminatedTreatmentBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Acute Myeloid Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1TerminatedTreatmentTumors, Solid1
1WithdrawnTreatmentCNS 2a / CNS 2b / CNS 2c / CNS1 / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
1, 2Active Not RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Unresectable Pancreatic Carcinoma1
1, 2RecruitingTreatmentCentral Nervous System Embryonal Tumor With Rhabdoid Features / Central Nervous System Embryonal Tumor, Not Otherwise Specified / Central Nervous System Ganglioneuroblastoma / Childhood Central Nervous System Neoplasm / Childhood Solid Neoplasm / Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Pinealoblastoma / Primary Central Nervous System Neoplasm / Recurrent Childhood Central Nervous System Embryonal Neoplasm / Recurrent Childhood Medulloblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Malignant Solid Neoplasm / Recurrent Medulloblastoma / Recurrent Neuroblastoma / Recurrent Rhabdomyosarcoma / Recurrent Solid Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Medulloblastoma / Refractory Neuroblastoma / Refractory Rhabdomyosarcoma1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2TerminatedTreatmentCervical Cancers1
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Carcinosarcoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Ovarian Undifferentiated Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
2Active Not RecruitingTreatmentOvarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation1
2CompletedTreatmentCancer of the Ovary1
2CompletedTreatmentPreviously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer1
2RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
2RecruitingTreatmentAdvanced Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Bladder Carcinoma / Carcinoma, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Cervical Carcinoma / Colon Carcinoma / Endometrial Carcinoma / Gastric Carcinoma / Gliomas / Head and Neck Carcinoma / Liver and Intrahepatic Bile Duct Carcinoma / Lung, Carcinoma / Malignant Lymphomas / Malignant Uterine Neoplasm / Melanoma / Oesophageal Carcinoma / Ovarian Carcinoma / Plasma Cell Myeloma / Prostate Cancer / Rectal Carcinoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Cervical Carcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Gliomas / Recurrent Head and Neck Carcinoma / Recurrent Liver Carcinoma / Recurrent Lung Carcinoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Plasma Cell Myeloma / Recurrent Prostate Carcinoma / Recurrent Rectal Carcinoma / Recurrent Skin Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Uterine Corpus Carcinoma / Refractory Lymphomas / Refractory Malignant Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Renal Carcinoma / Skin Carcinoma / Solid Neoplasms / Thyroid Gland Carcinoma / Uterine Corpus Cancer1
2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / CCNE1 Gene Amplification / Refractory Malignant Solid Neoplasm1
2RecruitingTreatmentLocally Advanced Malignant Solid Neoplasm / Locally Advanced Solid Neoplasm / Metastatic Malignant Solid Neoplasm1
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentMalignancies1
2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Refractory Ovarian Carcinoma1
2RecruitingTreatmentTriple-negative Metastatic Breast Cancer1
2RecruitingTreatmentUterine Malignancies1
2SuspendedTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasms / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentPreviously Treated Non Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2Unknown StatusTreatmentOvarian Epithelial Cancer1
Not AvailableSuspendedTreatmentAdvanced Malignant Solid Neoplasm / Neoplasms / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Solid Neoplasm1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0625 mg/mLALOGPS
logP3.3ALOGPS
logP3.17ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.69ChemAxon
pKa (Strongest Basic)7.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area100.96 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity155.95 m3·mol-1ChemAxon
Polarizability54.19 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Pyrazolylpyridines / Pyrazolo[3,4-d]pyrimidines / Aniline and substituted anilines / Dialkylarylamines / Aminopyrimidines and derivatives / N-methylpiperazines / Pyrazolones / Vinylogous amides / Tertiary alcohols
show 10 more
Substituents
Phenylpiperazine / N-arylpiperazine / 2-pyrazolylpyridine / Pyrazolopyrimidine / Pyrazolo[3,4-d]pyrimidine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Aminopyrimidine / N-alkylpiperazine
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein tyrosine kinase activity
Specific Function
Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating ph...
Gene Name
WEE1
Uniprot ID
P30291
Uniprot Name
Wee1-like protein kinase
Molecular Weight
71596.655 Da
References
  1. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov;8(11):2992-3000. doi: 10.1158/1535-7163.MCT-09-0463. Epub 2009 Nov 3. [PubMed:19887545]

Drug created on October 20, 2016 14:43 / Updated on November 02, 2018 07:14